Related Experiment Videos
Torsade de pointes probably induced by sparfloxacin
1Department of Internal Medicine, Sir Ganga Ram Hospital New Delhi.
The Journal of the Association of Physicians of India
|November 8, 2002
Summary
Sparfloxacin, a potent antitubercular fluoroquinolone, was administered to a 37-year-old female. She subsequently developed torsade de pointes, a serious cardiac arrhythmia, during treatment.
Area of Science:
- Pharmacology
- Cardiology
- Infectious Diseases
Background:
- Sparfloxacin is a novel fluoroquinolone antibiotic.
- It exhibits significant activity against Mycobacterium tuberculosis.
- Antitubercular therapy regimens are continually being modified to improve efficacy and manage resistance.
Observation:
- A case study involving a 37-year-old female patient is presented.
- The patient was undergoing a modified antitubercular therapy regimen.
- Sparfloxacin was a component of her prescribed medication.
Findings:
- The patient developed torsade de pointes, a specific type of polymorphic ventricular tachycardia.
- This cardiac event occurred during the course of sparfloxacin treatment.
- The case highlights a potential adverse cardiac effect of sparfloxacin.
Implications:
- This case suggests a potential cardiotoxic risk associated with sparfloxacin use.
- Clinicians should be vigilant for cardiac arrhythmias in patients treated with sparfloxacin.
- Further investigation into the cardiac safety profile of sparfloxacin is warranted.